179 related articles for article (PubMed ID: 28178655)
1. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer.
Martín-Sánchez E; Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Blanco-Luquin I; Córdoba A; Vicente-García F; Pérez-Janices N; Escors D; Megías D; López-Serra P; Esteller M; Illarramendi JJ; Guerrero-Setas D
Oncotarget; 2017 Feb; 8(9):15789-15801. PubMed ID: 28178655
[TBL] [Abstract][Full Text] [Related]
2.
Martín-Sánchez E; Mendaza S; Ulazia-Garmendia A; Monreal-Santesteban I; Córdoba A; Vicente-García F; Blanco-Luquin I; De La Cruz S; Aramendia A; Guerrero-Setas D
Clin Epigenetics; 2017; 9():7. PubMed ID: 28149335
[TBL] [Abstract][Full Text] [Related]
3. Expression and promoter methylation status of OPCML and its functions in the inhibition of cell proliferation, migration, and invasion in breast cancer.
Lian B; Li H; Liu Y; Chai D; Gao Y; Zhang Y; Zhou J; Li J
Breast Cancer; 2021 Mar; 28(2):448-458. PubMed ID: 33108608
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
5. Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
Böck J; Appenzeller S; Haertle L; Schneider T; Gehrig A; Schröder J; Rost S; Wolf B; Bartram CR; Sutter C; Haaf T
Int J Cancer; 2018 Sep; 143(6):1416-1425. PubMed ID: 29659014
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Significance of Promoter DNA Hypermethylation of cysteine dioxygenase 1 (CDO1) Gene in Primary Breast Cancer.
Minatani N; Waraya M; Yamashita K; Kikuchi M; Ushiku H; Kojo K; Ema A; Nishimiya H; Kosaka Y; Katoh H; Sengoku N; Tanino H; Sidransky D; Watanabe M
PLoS One; 2016; 11(1):e0144862. PubMed ID: 26785325
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous CXCL12 and ESR1 CpG island hypermethylation correlates with poor prognosis in sporadic breast cancer.
Ramos EA; Camargo AA; Braun K; Slowik R; Cavalli IJ; Ribeiro EM; Pedrosa Fde O; de Souza EM; Costa FF; Klassen G
BMC Cancer; 2010 Jan; 10():23. PubMed ID: 20109227
[TBL] [Abstract][Full Text] [Related]
8. CpG hypermethylation of collagen type I alpha 2 contributes to proliferation and migration activity of human bladder cancer.
Mori K; Enokida H; Kagara I; Kawakami K; Chiyomaru T; Tatarano S; Kawahara K; Nishiyama K; Seki N; Nakagawa M
Int J Oncol; 2009 Jun; 34(6):1593-602. PubMed ID: 19424577
[TBL] [Abstract][Full Text] [Related]
9. A disintegrin and metalloprotease 23 hypermethylation predicts decreased disease-free survival in low-risk breast cancer patients.
Zmetakova I; Kalinkova L; Smolkova B; Horvathova Kajabova V; Cierna Z; Danihel L; Bohac M; Sedlackova T; Minarik G; Karaba M; Benca J; Cihova M; Buocikova V; Miklikova S; Mego M; Fridrichova I
Cancer Sci; 2019 May; 110(5):1695-1704. PubMed ID: 30815959
[TBL] [Abstract][Full Text] [Related]
10. Wnt signalling in human breast cancer: expression of the putative Wnt inhibitor Dickkopf-3 (DKK3) is frequently suppressed by promoter hypermethylation in mammary tumours.
Veeck J; Bektas N; Hartmann A; Kristiansen G; Heindrichs U; Knüchel R; Dahl E
Breast Cancer Res; 2008; 10(5):R82. PubMed ID: 18826564
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation of the SFRP2 gene is a high-frequent alteration and tumor-specific epigenetic marker in human breast cancer.
Veeck J; Noetzel E; Bektas N; Jost E; Hartmann A; Knüchel R; Dahl E
Mol Cancer; 2008 Nov; 7():83. PubMed ID: 18990230
[TBL] [Abstract][Full Text] [Related]
12. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of DNAJC10 (ERDJ5) is associated with poor survival in breast cancer.
Acun T; Senses KM
Breast Cancer; 2020 May; 27(3):483-489. PubMed ID: 31902119
[TBL] [Abstract][Full Text] [Related]
14. KRAB zinc-finger protein 382 regulates epithelial-mesenchymal transition and functions as a tumor suppressor, but is silenced by CpG methylation in gastric cancer.
Pei L; He X; Li S; Sun R; Xiang Q; Ren G; Xiang T
Int J Oncol; 2018 Sep; 53(3):961-972. PubMed ID: 29956735
[TBL] [Abstract][Full Text] [Related]
15. Differential Prognostic Relevance of Promoter DNA Methylation of
Tanaka Y; Kosaka Y; Waraya M; Yokota K; Harada H; Kaida T; Kikuchi M; Minatani N; Nishimiya H; Katoh H; Sengoku N; Watanabe M; Yamashita K
Anticancer Res; 2019 May; 39(5):2289-2298. PubMed ID: 31092420
[TBL] [Abstract][Full Text] [Related]
16. Adherens junctions associated protein 1 serves as a predictor of recurrence of squamous cell carcinoma of the esophagus.
Tanaka H; Kanda M; Koike M; Iwata N; Shimizu D; Ezaka K; Sueoka S; Tanaka Y; Takami H; Hashimoto R; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Fujiwara M; Kodera Y
Int J Oncol; 2015 Nov; 47(5):1811-8. PubMed ID: 26397940
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of SIX3 is associated with clinical outcome in lung adenocarcinoma.
Mo ML; Okamoto J; Chen Z; Hirata T; Mikami I; Bosco-Clément G; Li H; Zhou HM; Jablons DM; He B
PLoS One; 2013; 8(8):e71816. PubMed ID: 23977152
[TBL] [Abstract][Full Text] [Related]
18. TET1 downregulates epithelial-mesenchymal transition and chemoresistance in PDAC by demethylating CHL1 to inhibit the Hedgehog signaling pathway.
Li H; Jiang W; Liu XN; Yuan LY; Li TJ; Li S; Xu SS; Zhang WH; Gao HL; Han X; Wang WQ; Wu CT; Yu XJ; Xu HX; Liu L
Oncogene; 2020 Sep; 39(36):5825-5838. PubMed ID: 32753651
[TBL] [Abstract][Full Text] [Related]
19. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
20. The 3p14.2 tumour suppressor ADAMTS9 is inactivated by promoter CpG methylation and inhibits tumour cell growth in breast cancer.
Shao B; Feng Y; Zhang H; Yu F; Li Q; Tan C; Xu H; Ying J; Li L; Yang D; Peng W; Tang J; Li S; Ren G; Tao Q; Xiang T
J Cell Mol Med; 2018 Feb; 22(2):1257-1271. PubMed ID: 29193730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
